Latest Earnings Results: Q3 '26
Estimated EPS
-$0.02
Reported EPS
$0.05
Surprise
+350%
Estimated Rev
$12.42M
Reported Rev
$21.92M
Surprise
+76.53%
Protalix BioTherapeutics reported Q3 2026 total revenue of $21.93M, net income of $3.96M, and diluted EPS of $0.05; selling-goods revenue was $21.83M, up 23.5% year over year.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.04 | -- | -- | N/A |
Q3 '26 | -$0.02 | $0.05 | 350.00% | BEAT |
Q2 '26 | -$0.01 | $0.05 | 600.00% | BEAT |
Q1 '26 | -$0.01 | $0.22 | 2300.00% | BEAT |
Q4 '25 | $0.04 | -$0.06 | -250.00% | MISSED |